Stay updated with breaking news from Simon Latimer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Ligand will receive 13% of all soticlestat royalties and milestone payments owed to OvidOvid secures a $30 million non-dilutive capital infusion from Ligand, which Ovid expects to extend its cash...
Ligand retains all Pelican commercial royalties and will own 49.9% of Primrose Bio, Inc. as a stand-alone private company with leading technologies in synthetic biologyLigand contributes $15 million in exchange for economic interest in select Primrose programsLigand improves cash expense outlook and raises EPS guida...
Operator: Thank you for standing by. My name is Kyla Baker and I will be your conference operator today.
Operator: Good evening. My name is Rob and I will be your conference operator today. At this time, I would like to welcome everyone to the Ligand Pharmaceuticals Fourth Quarter 2022 Earnings Webcast.
First single molecule Dual Endothelin Angiotensin Receptor Antagonist (DEARA) approved for use in patients with IgA nephropathy (IgAN)Interim results from the ongoing Phase 3 PROTECT head-to-head trial demonstrated a rapid, sustained and clinically meaningful reduction in proteinuria vs. active control, irbesartanLi...